The Human body is a vast network of interacting genes, proteins, and metabolites. These components, which may be considered host factors, change under disease, treatment or healthy condition. While treatment of many diseases depends on therapeutic drugs, vaccines remain the most effective long-term public health intervention to prevent infectious diseases. To date, vaccines have been developed to treat entire populations with little provision for predisposing individual host factor differences. However, the use and application of vaccines is facing multiple challenges with increasing numbers of vaccine non-responders and vaccine-relapsed individuals. The cause of this complication is partially due to host-factors. Another challenge is the adverse effects of vaccines in patients with primary immunodeficiency or autoimmune diseases, as well as vaccine-waning immunity in ageing populations, obese populations, or those with co-infection. To overcome these challenges, the solution may be the design, and formulation of precision vaccines, which are patient-specific.
Design of precision vaccines requires in-depth understanding of the host-pathogen interaction, This can be achieved by taking advantage of an array of microbiological, molecular and bioinformatic ("omic") techniques that have been developed or vastly improved upon. This enables new vaccines to be specifically identified, designed, produced, and delivered with the aim of optimizing the induction of a protective immune response using well-defined formulations. In addition to the host, omics information on the pathogen is required to identify suitable precision vaccines candidates.
Vaccines are the main preventive measure for infectious diseases. However, the number of vaccine non-responders are increasing. Since this is related to host factors, customization of vaccines will require use of omics platforms to overcome the knowledge gap on the immune response to a specific pathogen. Since precision vaccine for infectious disease is still at its infancy, success in this area will require research, publication, and collaboration from multidisciplinary areas. The aim of this Research Topic is to foster the discussion around different disciplines of precision vaccine development, such as systems vaccinology, omics development, human in vitro modeling, adjuvant discovery and development, and bioinformatics.
We welcome the submission of Original Research, Review, Mini-review, Perspective, and Clinical trial articles, focusing on, but not limited to, the following sub-topics:
• Advances in gene delivery and expression, proteins, and adjuvants leading to the creation of new vaccine platforms
• New approaches to identify specific genomic profiles (non-responder individuals)
• Advances in the use of Omics data to create novel bioinformatic tools to predict the vaccination outcome
• In vitro modeling of human immunity to vaccines
• Development of new vaccines for vulnerable populations
• Mechanistic studies on evasion properties of infectious organisms
• HLA genotyping
The Human body is a vast network of interacting genes, proteins, and metabolites. These components, which may be considered host factors, change under disease, treatment or healthy condition. While treatment of many diseases depends on therapeutic drugs, vaccines remain the most effective long-term public health intervention to prevent infectious diseases. To date, vaccines have been developed to treat entire populations with little provision for predisposing individual host factor differences. However, the use and application of vaccines is facing multiple challenges with increasing numbers of vaccine non-responders and vaccine-relapsed individuals. The cause of this complication is partially due to host-factors. Another challenge is the adverse effects of vaccines in patients with primary immunodeficiency or autoimmune diseases, as well as vaccine-waning immunity in ageing populations, obese populations, or those with co-infection. To overcome these challenges, the solution may be the design, and formulation of precision vaccines, which are patient-specific.
Design of precision vaccines requires in-depth understanding of the host-pathogen interaction, This can be achieved by taking advantage of an array of microbiological, molecular and bioinformatic ("omic") techniques that have been developed or vastly improved upon. This enables new vaccines to be specifically identified, designed, produced, and delivered with the aim of optimizing the induction of a protective immune response using well-defined formulations. In addition to the host, omics information on the pathogen is required to identify suitable precision vaccines candidates.
Vaccines are the main preventive measure for infectious diseases. However, the number of vaccine non-responders are increasing. Since this is related to host factors, customization of vaccines will require use of omics platforms to overcome the knowledge gap on the immune response to a specific pathogen. Since precision vaccine for infectious disease is still at its infancy, success in this area will require research, publication, and collaboration from multidisciplinary areas. The aim of this Research Topic is to foster the discussion around different disciplines of precision vaccine development, such as systems vaccinology, omics development, human in vitro modeling, adjuvant discovery and development, and bioinformatics.
We welcome the submission of Original Research, Review, Mini-review, Perspective, and Clinical trial articles, focusing on, but not limited to, the following sub-topics:
• Advances in gene delivery and expression, proteins, and adjuvants leading to the creation of new vaccine platforms
• New approaches to identify specific genomic profiles (non-responder individuals)
• Advances in the use of Omics data to create novel bioinformatic tools to predict the vaccination outcome
• In vitro modeling of human immunity to vaccines
• Development of new vaccines for vulnerable populations
• Mechanistic studies on evasion properties of infectious organisms
• HLA genotyping
